Loading...

World-Class Retina Care. Community-Based Caring.

Initial Results of Phase Ib LOTUS Clinical Trial on Potential New Diabetic Macular Edema Treatment Released

Posted On June 16, 2025 / By / Posted in Blog

Initial Results of Phase Ib LOTUS Clinical Trial on Potential New Diabetic Macular Edema Treatment Released

On June 9, 2025, Eluminex Biosciences Limited, a clinical-stage protein therapeutics company, announced positive topline safety, tolerability, and pharmacodynamic data from the multicenter LOTUS Part 1 clinical trial of EB-105 in patients

read more
Posted On June 5, 2025 / By / Posted in Blog

Dr. Abbey Discusses How Vorolanib Could Shift the Treatment Approach for Diabetic Macular Edema in New Retinal Physician Article

Texas Retina’s Ashkan M. Abbey, MD, served as a principal site investigator for the Phase II VERONA clinical trial evaluating the efficacy and safety of the vorolanib intravitreal insert (EYP-1901) in diabetic

read more
Posted On October 9, 2024 / By / Posted in Blog

Dr. Abbey Participated in Roundtable Discussion on Newer Therapies for Wet AMD and Diabetic Macular Edema

Texas Retina’s Ashkan Abbey, MD, recently participated in a roundtable discussion on “Navigating Wet AMD and DME Using Newer Therapies” available on Eyetube. Dr. Abbey and fellow panelist Scott Walter, MD, MSc,

read more
Posted On September 20, 2024 / By / Posted in Blog

New Clinical Trials Available at Texas Retina

At Texas Retina, we remain committed to conducting ongoing research that will advance retinal care. That is why for over 20 years, for physicians have participated in more than 100 national clinical

read more
Posted On August 2, 2024 / By / Posted in Blog

Dr. Abbey First in the World to Administer Novel Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema as Part of Phase Ib LOTUS Clinical Trial

On July 9, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase Ib LOTUS trial of EB-105, the world’s first pentavalent trispecific

read more
Posted On May 29, 2024 / By / Posted in Blog

New Clinical Trials at Texas Retina

Over the past two decades, Texas Retina physicians have participated in more than 100 national clinical trials, offering our patients access to promising new treatments for a variety of retina conditions, including

read more
Posted On January 31, 2024 / By / Posted in Blog

New Clinical Trials Available at Texas Retina

At Texas Retina Associates, we remain committed to conducting ongoing research that will improve care for our patients, and over the past 20 years, our research program has grown to become one

read more
Posted On October 31, 2023 / By / Posted in Blog

Three New Clinical Trials Available at Texas Retina

Medical researchers continue to make significant advances in the diagnosis and treatment of retinal conditions, and our physicians remain committed to participating in clinical trials that will improve care for our patients.

read more
Posted On October 18, 2023 / By / Posted in Blog

New Treatment for Wet AMD and Diabetic Eye Disease Reduces Treatment Burden for Patients by Extending Dosing Intervals

On August 18, 2023, the U.S. Food and Drug Administration (FDA) approved Eylea HD (aflibercept), a high-dose version of Eylea, for the treatment of several retinal conditions, including advanced neovascular age-related macular

read more
Posted On October 2, 2023 / By / Posted in Blog

New Clinical Trials Available at Texas Retina

Our physicians remain committed to participating in ongoing retina research, providing our patients with access to promising new treatments through clinical trials. In fact, our research program has grown to become one

read more